PREP inhibitors have been shown to enhance the clearance of α-synuclein aggregates via autophagy activation and to reduce oxidative stress in cellular and animal models of Parkinson’s disease as well as in ARPE-19 cells with defunct proteasome activity [5,7,22,25,26]. This evidence concerns the gene PREP and Parkinson disease.